Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Given Average Recommendation of “Moderate Buy” by Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has earned an average recommendation of “Moderate Buy” from the nine research firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, five have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $18.3333.

EPRX has been the topic of several recent research reports. Zacks Research upgraded Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. William Blair initiated coverage on Eupraxia Pharmaceuticals in a research report on Monday, March 23rd. They set an “outperform” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Wall Street Zen cut Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st.

Eupraxia Pharmaceuticals Stock Up 0.2%

Shares of EPRX opened at $6.04 on Friday. Eupraxia Pharmaceuticals has a 52 week low of $3.85 and a 52 week high of $9.32. The firm has a market cap of $392.72 million, a P/E ratio of -5.75 and a beta of 0.97. The firm’s 50-day simple moving average is $6.97 and its 200 day simple moving average is $7.37. The company has a debt-to-equity ratio of 0.02, a quick ratio of 19.31 and a current ratio of 19.31.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, analysts forecast that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in EPRX. Integrated Wealth Concepts LLC bought a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth $71,000. Bank of America Corp DE increased its position in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after buying an additional 10,059 shares during the period. Aptus Capital Advisors LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter worth $76,000. Guardian Wealth Advisors LLC NC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter worth $76,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 4th quarter worth $105,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.